Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
The company, a leading manufacturer of CPAP machines used to treat sleep apnea, faces a nuanced challenge from GLP-1-based medications. The core issue: obesity drives the vast majority of obstructive sleep apnea cases, with 70-90% of sufferers experiencing the condition due to excess weight. As patients lose weight through GLP-1 treatments, their need for breathing assistance devices may disappear entirely.
Source Fool.com
Resmed Inc. Aktie
195,80 €
0,36 %
Deutliche Buy-Präferenz bei Resmed Inc. ohne Sell-Einschätzungen.
Ein Kursziel von 256 € für Resmed Inc. signalisiert eine potenzielle Steigerung von über 20% gegenüber dem aktuellen Kurs von 195.8 €.
